Clinical Trial

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.
Protocol Amendment History 7 changes
notable Trial sites expanded: 57 -> 61 locations 2026-06-06
notable Trial sites expanded: 52 -> 57 locations 2026-05-23
notable Trial sites expanded: 42 -> 52 locations 2026-05-09
notable Trial sites expanded: 25 -> 42 locations 2026-04-25
notable Trial sites expanded: 20 -> 25 locations 2026-04-14
notable Primary completion pushed: 2028-04-04 -> 2028-05-18 2026-04-14
minor Completion pushed: 2028-07-04 -> 2028-09-14 2026-04-14
Trial Details
NCT Number NCT07290036
Lead Sponsor UCB Biopharma SRL
Conditions Psoriatic Arthritis, Axial Spondyloarthritis
Enrollment 392 participants
Start Date 2025-12-10
Primary Completion 2028-05-18 (estimated)
Study Completion 2028-09-14 (estimated)
Updated on ClinicalTrials.gov 2026-07-06